Brokerages expect Nevro Corp (NYSE:NVRO) to announce earnings of ($1.03) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Nevro’s earnings. The highest EPS estimate is ($0.94) and the lowest is ($1.15). Nevro reported earnings of ($0.91) per share in the same quarter last year, which would suggest a negative year over year growth rate of 13.2%. The firm is expected to issue its next earnings results on Thursday, August 13th.

According to Zacks, analysts expect that Nevro will report full year earnings of ($3.86) per share for the current financial year, with EPS estimates ranging from ($4.66) to ($2.28). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.95) to ($1.25). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Nevro.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Tuesday, May 5th. The medical equipment provider reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.21. The company had revenue of $87.47 million for the quarter, compared to the consensus estimate of $86.70 million. Nevro had a negative return on equity of 40.67% and a negative net margin of 21.36%. The company’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.45) earnings per share.

A number of research firms have recently issued reports on NVRO. SunTrust Banks reiterated a “buy” rating and issued a $135.00 target price on shares of Nevro in a research note on Thursday, June 4th. UBS Group upgraded shares of Nevro from a “sell” rating to a “neutral” rating and lifted their target price for the company from $100.00 to $132.00 in a research note on Monday, June 8th. Morgan Stanley lifted their target price on shares of Nevro from $135.00 to $145.00 in a research note on Thursday, June 18th. JPMorgan Chase & Co. lifted their target price on shares of Nevro from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Finally, Wells Fargo & Co cut their target price on shares of Nevro from $158.00 to $126.00 and set an “overweight” rating for the company in a research note on Thursday, April 2nd. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $124.15.

In other Nevro news, Director Shawn Mccormick sold 1,020 shares of Nevro stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $126.50, for a total transaction of $129,030.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVRO. Victory Capital Management Inc. grew its holdings in shares of Nevro by 8,071.0% in the 4th quarter. Victory Capital Management Inc. now owns 395,231 shares of the medical equipment provider’s stock valued at $46,456,000 after buying an additional 390,394 shares during the period. Perceptive Advisors LLC grew its holdings in shares of Nevro by 43.0% in the 1st quarter. Perceptive Advisors LLC now owns 1,092,068 shares of the medical equipment provider’s stock valued at $107,449,000 after buying an additional 328,182 shares during the period. BlackRock Inc. grew its holdings in shares of Nevro by 9.0% in the 1st quarter. BlackRock Inc. now owns 2,974,055 shares of the medical equipment provider’s stock valued at $297,347,000 after buying an additional 246,232 shares during the period. Norges Bank acquired a new position in shares of Nevro in the 4th quarter valued at $27,803,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Nevro in the 4th quarter valued at $26,341,000. 97.43% of the stock is owned by hedge funds and other institutional investors.

NYSE NVRO traded up $1.37 during trading on Tuesday, reaching $119.47. 504,577 shares of the company traded hands, compared to its average volume of 495,589. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.26 and a current ratio of 6.79. The stock’s 50 day moving average price is $123.69 and its two-hundred day moving average price is $118.86. The company has a market cap of $4.03 billion, a price-to-earnings ratio of -44.08 and a beta of 0.91. Nevro has a 1-year low of $60.51 and a 1-year high of $148.05.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Further Reading: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.